Drug Trial Radar · NCT04171700
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
Last checked: Nov 20, 2026Latest source record: Oct 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
83
Actual
Start
Jan 16, 2020
Primary completion
Jun 8, 2022
Study completion Jul 15, 2022
Sponsor
- Lead sponsor
- pharmaand GmbHIndustry
- Sponsor type
- Industry
- First posted
- Nov 21, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.
Conditions
- Solid Tumor
Interventions
RucaparibDrug
Oral rucaparib will be administered twice daily. The starting dose will be 600 mg daily (BID).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best Overall Response Rate by InvestigatorTime frame: From first dose of study drug until disease progression (up to approximately 2 years)
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
UCLA Medicine Hematology and Oncology
Los Angeles, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Florida Cancer Specialists
Fort Myers, Florida
Florida Cancer Specialists
St. Petersburg, Florida
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois
University of Iowa Hospital and Clinics
Iowa City, Iowa
Beth Israel Deaconess Medical Cancer Surgical Pavilion
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Columbia University Irving Medical Center
New York, New York
New York Cancer and Blood Specialists
Port Jefferson Station, New York
New York Cancer And Blood Specialists
The Bronx, New York
Ohio State University
Columbus, Ohio
Stephenson Cancer Center - The University of Oklahoma
Oklahoma City, Oklahoma
University of Pennsylvania
Philadelphia, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
SCRI/Tennessee Oncology - Chattanooga
Chattanooga, Tennessee
Tennessee Oncology
Nashville, Tennessee
Seattle Cancer Care Alliance/University of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.